The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.

Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.

A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.